Pharma IQ Members

Mark
McHale

Mark McHale

Dr Mark McHale is Chief Scientific Officer and Founder of ASLAN Pharmaceuticals. Previously, Mark was the Head of Molecular Sciences at AstraZeneca Respiratory & Inflammation and in this role supported small molecule and therapeutic antibody projects from target identification to phase IIa. Mark was a core member of the respiratory strategy team for the the research area (comprising 720 staff across 3 sites) for half a decade and personally lead all new target identification in asthma. In 2006, he led a $136M investment in the AZ/Dynavax collaboration to produce inhaled TLR9 agonists for the treatment of asthma and led the ongoing preclinical / phase I projects.

Prior to 2001, Mark worked for 7 years at SmithKline Beecham, where he supported lead optimisation projects in serotonin and dopamine receptors as well as working on leptin and the PPAR gamma agonist Avandia with Dr Steve Smith. In 1994, he transferred to the Neuroscience Department working with Dr Jackie Hunter, during which time he set up two new molecular science laboratories and formed a successful team to support molecular analysis of stroke and pain in order to characterise disease and identify new targets from a large strategic collaboration SmithKline had initiated with Human Genome Sciences. 

Mark trained at the University of London and University of East Anglia UK in Molecular Biology.

 

In this interview, Mark McHale, CIO of ASLAN Pharmaceuticals, located in Singapore, shares insight into how a small-to-medium pharma company operates and continues to be on the crest of the wave....Full Article »
Tags: CRO|asia
In Part 2 of this Boardroom Series interview, Mark McHale, CSO of ASLAN Pharmaceuticals, located in Singapore, shares his insights on the biggest challenges in drug development right now and the best CROs in the industry to work with....Full Article »
In this exclusive interview, Dr Mark McHale, CSO of ASLAN Pharmaceuticals, located in Singapore, shares insight into how a small-to-medium pharma company operates and continues to be on the crest of the wave....Full Article »
Most big pharma are setting up operations in Asia, with China predicted to be the biggest market in pharmaceuticals by 2025. Mark McHale, Chief Scientific Officer at Aslan Pharmaceuticals discusses starting up Aslan in Singapore over two years ago, looking at the advantages and indeed challenges of operating in the East and the opportunities...Full Article »